Biotech | November 18, 2021
AstraZeneca’s Covid-19 drug offers 83% protection over six months
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
Two out of three people under the age of 40 are at risk of prediabetes
Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
The start-up has announced the scheme to mark World Diabetes Day
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Evidence also shows better immune response to virus among users of spray
Subscribe To Our Newsletter & Stay Updated
